{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:30:26Z","timestamp":1793734226470,"version":"4.6.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.4103\/ijo.ijo_3217_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:04Z","timestamp":1777478464000},"page":"627-629","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Anti-vascular endothelial growth factor conundrum"],"prefix":"10.4103","volume":"74","author":[{"given":"P Mahesh","family":"Shanmugam","sequence":"first","affiliation":[{"name":"Department of Vitreoretinal Services & Ocular Oncology, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20261103","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1038\/s41433-025-03996-8","article-title":"Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: Evaluating the unmet need in a real-world neovascular age-related macular degeneration national database","volume":"39","author":"Zarranz-Ventura","year":"2025","journal-title":"Eye (Lond)"},{"key":"R2-20261103","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/OPTH.S515479","article-title":"CompaRative safety analysis of innovator and biosimilar ranibizumab in chorioretinal vascular diseases-The CRsIBS study","volume":"19","author":"Chakraborty","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41433-024-03370-0","article-title":"Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration","volume":"39","author":"Teo","year":"2025","journal-title":"Eye (Lond)"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2016.208","article-title":"Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents","volume":"31","author":"Gemenetzi","year":"2017","journal-title":"Eye (Lond)"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ophtha.2019.11.010","article-title":"Anti-vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: Systematic literature review and expert opinion","volume":"127","author":"Sadda","year":"2020","journal-title":"Ophthalmology"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00417-024-06721-5","article-title":"Simultaneous GA and CNV\/MNV: Incidence, characteristics, and treatments","volume":"263","author":"Kataoka","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.ophtha.2020.06.019","article-title":"Macular atrophy incidence and progression in eyes with neovascular age-related macular degeneration treated with vascular endothelial growth factor inhibitors using a treat-and-extend or a Pro Re Nata regimen: Four-year results of the MANEX study","volume":"127","author":"Spooner","year":"2020","journal-title":"Ophthalmology"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/ceo.14559","article-title":"Real-world 10-year outcomes of anti-VEGF therapy for neovascular age-related macular degeneration: A meta-analysis","volume":"53","author":"Spooner","year":"2025","journal-title":"Clin Exp Ophthalmol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: A randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40123-025-01093-3","article-title":"To treat or not to treat? Resolving the question of subretinal and intraretinal fluid in age-related macular degeneration: A narrative review","volume":"14","author":"Foss","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41433-024-03308-6","article-title":"Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era","volume":"38","author":"Armendariz","year":"2024","journal-title":"Eye (Lond)"},{"key":"R13-20261103","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41433-023-02667-w","article-title":"Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients","volume":"38","author":"Rennie","year":"2024","journal-title":"Eye (Lond)"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10792-017-0695-z","article-title":"\u201cWhat should I inject next?\u201d Challenging treatment decisions in the multiple anti-VEGF: A review of publications exploring anti-VEGF switching for nAMD","volume":"38","author":"Pikkel","year":"2018","journal-title":"Int Ophthalmol"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10792-021-02113-4","article-title":"Dexamethasone implant improves anatomic response to anti-VEGF therapy in treatment-resistant polypoidal choroidal vasculopathy","volume":"42","author":"Mallikarjun","year":"2022","journal-title":"Int Ophthalmol"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.2147\/OPTH.S224456","article-title":"Adding a corticosteroid or switching to another anti-VEGF in insufficiently responsive wet age-related macular degeneration","volume":"13","author":"Kaya","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R18-20261103","first-page":"136","article-title":"Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity","volume":"7","author":"Darwish","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s40746-022-00249-8","article-title":"Current management of retinopathy of prematurity","volume":"8","author":"Tsai","year":"2022","journal-title":"Curr Treat Options Peds"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/s41433-025-03735-z","article-title":"Comparing safety and efficacy of bevacizumab, ranibizumab and ranibizumab biosimilar in retinopathy of prematurity","volume":"39","author":"Maitra","year":"2025","journal-title":"Eye (Lond)"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3217_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:30Z","timestamp":1793732430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3217_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3217_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}